Engflag

Iscador

Quick links to important sections

Iscador

Iscador_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iscador

What is Iscador? Overview and Quick Facts

Property Description
Active Ingredient Mistletoe Extract (Viscum album L.)
Form Solution for Injection
Pharmacological Class Anthroposophic Medicine, Immunomodulator
General Purpose Adjuvant Therapy / Supportive Care
Origin Plant-Based (Standardized, Fermented Extract)

What Type of Medicine is Iscador? (Definition and Classification)

Iscador is a specialized anthroposophic medicine and phytotherapeutic agent derived from the European Mistletoe (Viscum album L.). The preparation is broadly classified as an Immunomodulator and biological response modifier, a categorization describing its ability to interact with the immune system. Iscador functions as an adjuvant therapy, meaning its purpose is to complement other primary medical treatments by supporting the patient's biological resources. This unique classification stems from its development within anthroposophical medicine, a discipline with a long tradition of clinical application, which gives the preparation a distinct identity in the therapeutic landscape.

Iscador Composition and Plant-Based Origin

The fundamental composition of Iscador is a fermented, aqueous extract of the Mistletoe plant, containing active protein components such as Mistletoe lectins and viscotoxins. The most significant differentiating factor of Iscador is its specific biological origin, as the Mistletoe is deliberately harvested from different host trees, leading to variants such as Iscador M (Mistletoe from apple trees) and Iscador Qu (Mistletoe from oak). This distinction in source material affects the extract's biochemical profile. The preparation is considered appropriate for supportive use in certain conditions. The manufacturing process involves fermentation and strict standardization, ensuring a stable dosage form for the specific plant-based extract required.

Form and General Purpose of the Mistletoe Preparation

Iscador is supplied as a solution for injection in ampoules, which dictates its parenteral administration via subcutaneous injection. This injectable dosage form is critical because it ensures the integrity of the active protein components, which would otherwise be broken down if administered orally. The general purpose of the therapy is centered on enhancing the patient's general well-being, improving vitality, and supporting the body's self-regulatory mechanisms, thereby serving as supportive care throughout treatment regimens.

Regulatory References

  1. NIH Mistletoe Extracts PDQ

What side effects are possible with Iscador?

Possible side effects and safety information

The safety profile of Iscador (Mistletoe Extract) is formally documented in government regulatory sources, which classify observed effects by frequency and affected physiological systems.

Adverse Reaction Scope

Category Description
Key adverse reaction categories: Local reactions at the injection site (e.g., redness, swelling, induration) and systemic constitutional symptoms (e.g., fever, flu-like symptoms).
Frequency classification: Very Common or Expected Effects (local reaction le 5 cm, fever le 38 C); Common (general injection site reactions, mild fever, headache, leukocytosis); Uncommon (gastrointestinal, skin, and vascular effects); Rare (severe allergic/anaphylactic reactions).
System-organ classes involved: General disorders and administration site conditions, Skin and subcutaneous tissue disorders, Gastrointestinal disorders, Nervous system disorders, and Vascular disorders.
Serious adverse reactions: Systemic allergic reactions, including anaphylactic shock, which are documented in regulatory reports as Rare events.
Population-specific safety considerations: Contraindicated in individuals with a known hypersensitivity to mistletoe preparations, those with active florid autoimmune diseases, chronic granulomatous diseases, hyperthyroidism, or concurrent immunosuppressive therapy.
Dose- or exposure-related patterns: Systemic reactions are typically most prominent at the initiation of therapy; excessive local reactions (mathbf> 5 cm) or fever (mathbf> 38 C) are dose-dependent, signifying an overly intense reaction.
Safety-related restrictions or limitations: Administration is temporarily restricted if the patient’s body temperature is mathbf38 C or higher.

Safety Classifications (High-Level)

Element Description
Regulatory frequency framework used: European Summary of Product Characteristics (SmPC) / ICH frequency bands.
Context-of-use safety notes: Mild local reactions and slight temperature increases are often listed as expected effects, which, in this context, are considered indicators of an immune response.

Resulting safety structure

The label establishes a profile characterized by a high frequency of Common and Expected local and systemic reactions. The safety structure clearly differentiates these frequent events from mathbfRare, mathbfSerious Adverse Reactions such as anaphylaxis. Furthermore, the label defines critical mathbfPopulation Constraints, which restrict its use in individuals with pre-existing conditions like active autoimmune disease, thereby formally outlining the medicine’s specific risk limitations within the regulatory framework.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Iscador (Mistletoe Extract) overdose is defined by the recognition of specific, severe reactions that mandate immediate intervention.

Documented Overdose Manifestations

Overdose presentations are classified based on the severity of the body's reaction. Excessive local reactions at the injection site are typically defined as swelling that exceeds five centimeters in diameter. Strong general reactions include a systemic response such as an increase in core body temperature above 38 C, as well as flu-like symptoms, headache, nausea, or vomiting. Exposure to high dosages has also been associated with rare cases of transient liver toxicity.

Life-Threatening Outcomes and Emergency Actions

The most serious documented risk is a severe systemic response. The regulatory profile specifically notes the potential for anaphylaxis (a severe allergic reaction) and the acute toxicological potential for effects such as seizures and slowed heart rate (bradycardia), which are associated with high exposure to the plant’s toxic constituents.

If anaphylaxis or any potentially life-threatening reaction occurs, one must seek immediate medical attention. For strong general reactions, such as fever exceeding 38 C or excessive local reactions, treatment must be stopped immediately and an attending medical specialist should be consulted.

Supportive Management and Constraints

Overdose management is generally symptomatic and supportive. No specific antidote for Mistletoe Extract is explicitly documented in official regulatory summaries. Due to toxicity concerns, use is considered likely unsafe and should be avoided during both pregnancy and lactation.

Therapeutic Uses of Iscador

What Iscador Treats: Main Uses and Benefits

The therapeutic relevance of Iscador centers on its use as a supportive adjunct (adjuvant therapy) for patients with malignant tumors across common categories and certain defined precancerous disorders. The preparation is commonly used to provide long-term supportive care, complementing the primary treatment course, and it is often applied during complex treatment phases or may be relevant during the aftercare period.

Iscador is commonly used to address clusters of symptoms associated with intensive oncological treatments and disease progression. Its use is relevant for managing treatment-related side effects such as nausea, malaise, and appetite loss, and easing complex systemic constitutional symptoms like chronic cancer-related fatigue (exhaustion unrelieved by rest) and associated systemic strain.

By contributing to easing the overall symptom load, the therapy is considered relevant for supporting an improved comfort level and general well-being.

Quick Fact: Relief for Cancer-Related Symptoms
Iscador is relevant for managing symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort, which is linked to better appetite and vitality.

Regulatory References

  1. Mistletoe Extracts (PDQ®): Integrative, Alternative, and Complementary Therapies - NCI

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Iscador — Official Regulatory Information

The following information summarizes the officially documented population eligibility and non-eligibility rules for Iscador, strictly based on governmental regulatory sources and prescribing information.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults with malignant tumors or defined precancerous disorders who meet specific clinical health criteria.
Populations for whom use is not recommended (if applicable) Children and adolescents are generally not recommended as the product's effects and safety profile have not been fully investigated by regulators.
Populations for whom use is contraindicated Individuals with known hypersensitivity or allergy to mistletoe. Patients with florid autoimmune diseases or those with hyperthyroidism with tachycardia. Use is also prohibited during an acute inflammatory or infectious disease accompanied by high fever.
Age-related eligibility rules Adult Use is permitted. Pediatric Use is restricted, often classified as not established due to insufficient data.
Condition-specific eligibility rules Eligibility requires adequate hepatic and renal function for administration. Use is prohibited in patients with conditions like chronic granulomatous diseases.
Pregnancy and lactation eligibility status (if explicitly documented) Contraindicated or requires special caution because the effects on the fetus or infant have not been sufficiently investigated.
Eligibility-related restrictions Concomitant treatment with immunostimulant or immunosuppressive drugs (excluding cytotoxic agents) is cautioned against or contraindicated.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification (as defined in official documents) Absolute Contraindication (e.g., Hypersensitivity, Autoimmune Disease) and Restricted Use (e.g., Pediatric, Pregnancy/Lactation).
Regulatory basis SmPC / National Health Authority Prescribing Information.
Eligibility-context constraints (as defined in official documents) Prohibited in the context of active systemic inflammation or infectious disease (requiring temporary cessation).

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with known mistletoe allergy, florid autoimmune diseases, and hyperthyroidism with tachycardia.
  • Use is prohibited for women who are pregnant or breastfeeding because the effects have not been sufficiently investigated.
  • The regulatory profile restricts use in children, stating that the effects and safety profile are not fully established in the pediatric population.
  • Patients must not use the medicine during an acute inflammatory illness or when they have a high fever.

Connection to the overall eligibility profile: Governmental regulatory documents define who can and cannot use Iscador by imposing a core set of absolute contraindications based on immune status, hypersensitivity, and specific endocrine conditions. The profile further limits eligibility by categorizing pregnancy, lactation, and the pediatric population as groups where use is either prohibited or not recommended due to insufficient safety documentation, ensuring the medicine is used only under established labeled conditions.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The documented interaction profile for Iscador in official regulatory sources is defined by a specific precautionary restriction and the formal absence of dedicated pharmacokinetic study data. This profile is consistent with the product's regulatory classification.

A precautionary contraindication is advised by national regulatory authorities against the simultaneous use of Iscador with certain categories of medicinal products. This restriction applies to co-administration with other immunomodulators and immunostimulants, a measure based on the potential for interfering pharmacodynamic effects. It is important to note that this specific restriction explicitly excludes cytotoxic drugs (chemotherapy) used in primary cancer treatment, thereby defining the single documented interaction constraint.

Regarding effects on drug concentrations, the regulatory assessment confirms that no dedicated studies of drug-drug interactions have been conducted to evaluate Iscador's influence on the clearance or plasma exposure of co-administered medicines. Consequently, no pharmacokinetic (PK)-based constraints—such as mandatory time-separation rules between doses or required adjustments to the dosing of concurrent medication—are cited in the official regulatory documentation. No interactions with food, alcohol, or specific herbal products are officially documented. The official profile does not contain information on metabolic (CYP enzyme) or transporter-mediated interactions, nor are there population-specific interaction cautions for the elderly or those with hepatic impairment.

Mechanism of Action

Iscador's pharmacodynamic mechanism involves two principal classes of components: mistletoe lectins and viscotoxins. Mistletoe lectins act as ribosome-inactivating proteins, primarily targeting the 28S RNA of the 60S ribosomal subunit. This enzymatic hydrolysis inhibits the elongation step of protein biosynthesis, leading to a molecular and cellular pathway of cell death.

Downstream, this cellular stress triggers the mitochondrial (intrinsic) apoptotic pathway, characterized by the depolarization of the mitochondrial membrane and subsequent release of cytochrome C into the cytosol, which culminates in the activation of caspase-9 and caspase-3. Certain formulations may additionally activate the death receptor (extrinsic) pathway via caspase-8. This direct mechanism is complemented by an immunomodulatory cascade. Mistletoe lectins interact with immune cell receptors, acting as an agonist to stimulate the secretion of pro-inflammatory cytokines, including TNF-alpha and IFN-gamma.

Viscotoxins, which are small polypeptides, disrupt cell membrane integrity, leading to necrosis. Furthermore, Iscador preparations induce endoplasmic reticulum stress, causing the surface exposure of damage-associated molecular patterns (DAMPs) like calreticulin. The system-level physiological consequence is the modulation of the innate and adaptive immune responses and the induction of programmed and unprogrammed cell death.

Dosage and Administration Information

Administration Overview

Iscador is typically administered through subcutaneous injection, a method where the solution is introduced into the layer of fat directly under the skin. This process is generally performed using fine needles to minimize discomfort. The selection of the injection site is an important aspect of the routine, with common areas including the abdomen, upper thighs, or upper arms.

Injection Technique and Rotation

To maintain skin health and ensure consistent absorption, it is standard practice to rotate the injection sites. This involves choosing a different location for each subsequent administration, rather than using the exact same spot repeatedly. This rotation helps prevent localized skin changes or irritation.

Preparation and Handling

The preparation involves ensuring the solution is at an appropriate temperature and that the equipment used is sterile. The process is usually integrated into a patient’s regular schedule, often during the morning hours, though the specific timing is determined based on individual circumstances and the observations of the healthcare provider.

Monitoring the Injection Site

After an injection, it is common to observe the skin for localized reactions. These reactions are often viewed as an indicator of the body's response to the mistletoe extract. Patients are encouraged to take note of any changes at the site, such as mild redness or slight swelling, as these observations are useful for ongoing assessment during the course of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Iscador

This section outlines the landscape of clinical research, summarizing the types of studies that exist for Iscador, the outcomes they measured, and the overall consistency of the evidence, without providing clinical recommendations.

Evidence for Use in Adjuvant/Supportive Care

This section summarizes the high-level evidence available from systematic reviews, meta-analyses, and observational studies that have examined the use of Iscador alongside standard oncological treatments across various types of solid tumors. The focus is on studies that measured Overall Survival (OS) and Progression-Free Survival (PFS) outcomes, where the evidence quality has been assessed as generally low to moderate.

Research exploring Iscador in the context of supportive care for patients with malignant tumors has been conducted using several study designs, including aggregated data from meta-analyses that combine results from multiple studies, and long-term observational cohort studies with extended follow-up. Outcomes related to life expectancy, specifically Overall Survival (OS) and Progression-Free Survival (PFS), was studied for various common malignant tumors, often alongside conventional treatments. When data from numerous studies were combined in reviews, findings describe patterns observed in the studies that included patterns of lower mortality measurements were observed in patients receiving Iscador compared to those receiving no extra treatment. However, different patterns were observed when looking only at the smaller number of fully Randomized Controlled Trials (RCTs).

Evidence for Symptom Management and Quality of Life

This part details the findings from Randomized Controlled Trials (RCTs) and controlled clinical studies that specifically focused on patient-reported outcomes. It will describe the evidence regarding measures such as Health-Related Quality of Life (HRQoL) and standardized scales for symptoms like cancer-related fatigue, pain, nausea, and sleep disturbances in patients undergoing treatment.

These trials primarily examined patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance. Studies that monitored patients receiving Iscador alongside conventional treatment reported measurements on symptom scales that showed a less pronounced decline in quality of life scores and in specific symptoms like fatigue and sleep disturbances. The evidence is limited by the fact that many studies, particularly older ones, have an uncertain methodological quality. The uncertain methodological quality of many studies includes the frequent citation of unblinded designs.

Study Limitations and Research Gaps

A central limitation noted across systematic reviews is the evidence quality varies across studies, particularly the high number of older studies that lacked appropriate blinding. The inconsistency in findings between randomized and observational studies also presents a challenge for interpreting the overall research landscape. Another key research gap is the variability of the treatment itself, as the specific type of Mistletoe preparation and dosing are not uniform across all trials. Lastly, while much research was studied for adults with common tumors, subgroup findings are uncertain, and comparative evidence is lacking for many specific stages or rarer conditions.

Key Studies & References

  1. Mistletoe Extracts (PDQ®): Integrative, alternative, and complementary therapies - Health Professional Information [NCI]
  2. Mistletoe Extracts during the Oncological Perioperative Period: A Systematic Review and Meta-Analysis of Human Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Iscador (FAQ)

Q: What is the difference between Iscador M and Iscador Qu?

According to the official product information, Iscador is a plant-based extract derived from European Mistletoe (Viscum album L.). The different variants, such as Iscador M and Iscador Qu, are classified based on the host tree the mistletoe was harvested from. This distinction in the source material results in variations in the preparation's specific biochemical profile.

Q: How long does a course of Iscador therapy typically last?

Official administration guidelines indicate that the duration of Iscador therapy is highly individualized and is a decision made and supervised by the treating physician. The protocol involves an initial phase to find the optimal individual dose, followed by a long-term maintenance phase. Regulatory documentation defines the dose regimen structure but does not establish a standard, fixed treatment timeline.

--UNITS

Q: How long do I need to warm the ampoule before injecting?

Official handling instructions recommend that the Iscador ampoule be briefly warmed in the hand just prior to use. The regulatory guidance provides this information, but it does not define a specific duration in minutes for the warming process.

Q: What is the shelf life of Iscador ampoules?

The shelf life and expiration date for Iscador are determined by the manufacturer's stability studies and are printed on the ampoule and outer packaging. Official regulations require that the product should not be used past its expiration date.

Q: Is Iscador used to treat any conditions other than cancer, like arthritis or asthma?

The official regulatory approval documents focus on Iscador’s authorization for use as supportive care (adjuvant therapy) for malignant tumors and defined precancerous disorders. Information on its use for other conditions, such as arthritis or asthma, is not included in the official labeling.

Q: What is the best way to travel with Iscador?

Iscador requires continuous cold storage between +2 C and +8 C. Official guidance permits short cooling interruptions for transport, provided the temperature remains below 30 C for a duration of less than eight days. Detailed, specific travel protocols beyond the temperature rules are generally not outlined in the regulatory documentation.

Q: What should I do with my unused or expired Iscador?

Official regulatory instructions require that disposal of any unused or expired medicine must be carried out in accordance with local requirements for pharmaceutical waste. Used injection materials are typically disposed of in a safe container according to established guidelines.

How should Iscador be stored and disposed of?

Storage and Disposal Requirements for Iscador

Iscador solution for injection requires specific storage conditions as mandated by regulatory labeling to maintain the integrity of its active components.

Mandatory Storage and Handling

The product must be stored in a refrigerator within a strict temperature range of +2 C to +8 C (36 F to 46 F). Storage must not fall below 2 C; therefore, freezing is prohibited.

Although it is stored cold, the official guidance recommends that the ampoule be briefly warmed in the hand just prior to use. For transport, short cooling interruptions of less than eight days are permitted, provided the temperature does not exceed 30 C.

Disposal Instructions

Used injection materials, such as syringes, should have the protective cap replaced and be discarded safely. Disposal of any unused or expired medicine must be carried out in accordance with local regulatory requirements for pharmaceutical waste, ensuring proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Iscador found in:

A-Z Index: